Patients with plasma viral RNA 150,000 copies/mL, despite a protease-inhibitor regimen, received abacavir, amprenavir, and efavirenz to assess efavirenz-amprenavir drug interactions and to evaluate safety and antiviral response. Patients first received amprenavir with abacavir and other nucleoside analogs. Amprenavir levels were measured before and after adding efavirenz. Patients then received a second protease inhibitor. There was evidence of genotypic and phenotypic resistance at study entry. No patient had study drugs discontinued because of toxicity. Efavirenz decreased the steady-state area under the curve, maximum plasma concentration, and minimum plasma concentration of amprenavir by 24%, 33%, and 43%, respectively. Three of 10 patients had 11.5 log 10 viral response to abacavir and amprenavir. All 8 patients who added efavirenz had 10.5 log 10 decline in viral load, and this response lasted 124 weeks for 3 of the patients. A combination regimen that included abacavir, amprenavir, and efavirenz was well tolerated and had sustained activity in some patients. Concomitant efavirenz therapy decreases amprenavir concentrations.
Although combination antiretroviral therapy has prolonged survival in HIV-infected patients, failure of the regimen that manifests as increasing viral load is now a major issue in the care of these patients [1] [2] [3] [4] [5] . A variety of factors are thought to contribute to incomplete viral load response or loss of response: prior antiviral drug exposure; intermittent or continuous subtherapeutic drug levels resulting from drug interactions, poor oral absorption, or nonadherence to the prescribed regimen; high viral load at the start of therapy; and inadequate potency of the antiretroviral agents chosen [1, 4, 5] . In most cases, the final common pathway to failure is viral resistance to the antiviral agents. Resistance to all classes of antiretrovirals has been identified, and within-class cross-resistance is a substantial problem [6] . Thus, although antiretroviral treatment guidelines recommend using new antiviral agents for patients when therapy fails, it remains to be determined whether salvage regimens that are composed of the currently available classes of agents will effectively reduce the levels of circulating virus [1] . Clearly, the assessment of salvage regimens is a crucial need.
This study is a preliminary assessment of a combination regimen initially composed of abacavir and amprenavir, and then of abacavir, amprenavir, and efavirenz. The goals of this study were to assess drug interactions and tolerability, and to evaluate antiviral response in the context of baseline and on-drug genotyping of patients' plasma virus.
Methods
Eligible patients had previously enrolled in a study of indinavir with interleukin (IL)-2 and had a viral load of at least 50,000 copies/mL at the screening visit, despite receiving a protease inhibitor in combination with nucleoside analogs. Exclusion criteria included concomitant therapy with corticosteroids, chemotherapy, or investigational agents.
Patients were treated initially with amprenavir, 1200 mg twice daily, and abacavir, 300 mg twice daily, taken either while fasting or with patient-selected food according to patient preference. US Food and Drug Administration (FDA)-approved nucleoside analogs were permitted; other protease inhibitors and IL-2 were prohibited during the first 12 weeks of therapy, and other nonnucleoside reverse-transcriptase inhibitors (NNRTIs) were prohibited throughout the study. When efavirenz became available as an investigational agent for this study, patients were offered participation in an efavirenz-amprenavir drug interaction study. Patients who received amprenavir with nucleoside analogs for at least 1 week had serial blood samples collected over 12 h, and then efavirenz (600 mg po daily) was added to the regimen. After at least 1 week of efavirenz and amprenavir therapy, blood samples were again collected for the determination of amprenavir and efavirenz plasma concentrations. Efavirenz was not available for 8 of the patients when they began therapy with amprenavir and abacavir, so after this second sampling period, these 8 patients who began efavirenz 11 week after beginning amprenavir and abacavir also received a new protease inhibitor to avoid adding a single new agent [1] .
Amprenavir levels were measured by the high performance liquid chromatography (HPLC) at Glaxo Wellcome (Research Triangle Park, NC). Indinavir drug concentrations were measured by a validated HPLC [7] . Although the patients were still receiving indinavir, trough levels of indinavir were determined to document indinavir exposure. For determination of amprenavir pharmacokinetics, the means of the concentrations at time 0 and 12 h were used to define minimum concentrations. Maximum concentrations were determined directly from concentration-time profiles. Area under the curve (AUC) was calculated by use of standard noncompartmental techniques with the WinNonlin program, version 1.5 (Scientific Consulting, Cary, NC).
Viral load was measured by use of a branched DNA (bDNA) assay (Chiron, Emeryville, CA) with a limit of quantitation of 500 copies/mL. Values !500 copies/mL were scored as 499 for the purpose of data analysis. Assays were performed 4 weeks before the initiation of therapy, at baseline study entry, serially at weeks 2, 4, 6, 8, and then every 4 weeks for the remainder of the study. Laboratory tests including hematology profile, serum chemistry, and urinalysis were performed at each study visit.
Genotyping. HIV reverse transcriptase (RT) and protease sequences were obtained from cell-free patient plasma by use of RT-nested PCR procedures. Viral RNA isolated by use of QIAmp Viral RNA kit (Qiagen, Valencia CA) was used as a template for murine leukemia virus RT-directed reverse transcription reactions, using SA015 (5'-ACTCCATGTACTGGTTCTTTTAGA-3') as the downstream primer. HIV RT (amino acids 1-272) was amplified (35 cycles, 55ЊC) by use of AmpliTaq DNA Polymerase (PerkinElmer, Foster City, CA) from cDNA, using primers SA009 (5'-TTTAAATTTTCCCATTAGCCCTAT-3'), position 456 of pol (all nucleotide positions, except where indicated, are according to clone HXB2R [8] ) and SA015, position 1415. The PCR product was used as a template to amplify HIV RT sequence corresponding to amino acids 16-266 in a reaction (25 cycles, 55ЊC), using primers containing 5'-M13 sequences and corresponding to positions 511 (881MF, 5'-TGTAAAACGACGGCCAGTCCCGGGATGGAT-GGCCCAAAAGTTAAACAA-3') and 1299 (HIV-1 LAI) (891MR 5'-CAGGAAACAGCTATGACCGCTAGCCCAATTC-AATTTTCCCACTAA-3'). HIV protease gene sequences were amplified in reactions (35 cycles, 55ЊC) by use of primers PR1 (5'-GAAGCAGGAGCCGATAGACAAG-3', position 127) and PR2 (5'-CAGTCTCAATAGGGCTAATGGG-3', position 487); the PCR product was used as a template for nested PCR amplification reaction (25 cycles, 55ЊC) of a fragment encompassing the entire protease gene, using primers containing 5'-M13 sequences: PR3M (5'-TGTAAAACGACGGCCAGTGCCGATAGACAAGGAAC-TGTAT-3', position 136) and PR4M (5'-CAGGAAACAGCT-ATGACCTACTGGTACAGTCTCAATAGGG-3', position 495). In some reactions, a large 1289-nucleotide RT-protease fragment was amplified by use of primers PR1 and SA015 and was used as template for the second round of RT-and PR-nested PCR reactions by use of 881MF/891MR and PR3M/PR4M primer pairs, respectively. PCR products were purified by use of PCR Select III columns (5 Prime 3 Prime, Boulder, CO) and were then sequenced directly by use of M13 primers with a model 373 automated DNA sequencer (Perkin-Elmer), and the deduced nucleotide sequence was obtained by use of Fractura and AutoAssembler software (PerkinElmer).
Phenotyping. HIV-1 ERS104pre isolated from a drug-naive patient was used for drug susceptibility assays [9] . HIV-1 strains were isolated from study patients by culturing peripheral blood mononuclear cells (PBMC), as described elsewhere [10] . HIV-1 isolates were passaged once or twice in phytohemagglutinin (PHA)-stimulated PBMC; HIV-1-containing supernatants were stored at Ϫ70ЊC until use. Zidovudine was purchased from Sigma (St. Louis, MO). Amprenavir and abacavir were kind gifts from GlaxoWellcome. Indinavir was provided by Japan Energy (Tokyo). PHA-PBMC ( /mL) were exposed to 50 TCID 50 of each primary 6 1 ϫ 10 HIV-1 isolate in the presence or absence of various concentrations of drugs in 10-fold serial dilutions in 96-well microculture plates. All assays were performed in triplicate. The amounts of p24 antigen produced by the cells were determined on day 7 of culture by use of a commercially available radioimmunoassay kit (DuPont NEN, Boston, MA). Drug concentrations that resulted in 50% inhibition (IC 50 ) were determined by comparison with the p24 production level in drug-free control cell cultures [11, 12] . Sequences discussed in this work may be found in the GenBank database (accession numbers AF227687-AF227726).
Results
Patients. Eleven male patients were enrolled in the study. The median age at entry was 39 years (range, 33-50 years). The median entry viral load was 107,200 RNA copies/mL (range, 24,470-339,400 RNA copies/mL), and the median entry CD4 cell count was 205 cells/mL (range, 2-638 cells/mL; table 1). Patients enrolled between 1.3 and 3 years after enrollment in a study of indinavir (then an investigational agent) with IL-2. Seven had received IL-2 in the year before enrollment in this study. All patients were highly treatment-experienced and had received at least 1 year of indinavir; all had received saquinavir, 3 had received ritonavir, and 1 had received nelfinavir. All had received zidovudine, didanosine, stavudine, and lamivudine, and all but 1 had received zalcitabine. Three patients had received an NNRTI, 2 for !3 months and 1 for 6 months. One had received foscarnet.
Safety. Amprenavir, abacavir, and efavirenz were well tolerated and were not discontinued in any patient because of toxicity. There were no significant drug-related laboratory toxicities other than an asymptomatic elevation of serum lipase and amylase levels in 1 patient who was receiving amprenavir and abacavir. One patient had intermittent neutropenia, probably related to nonstudy medications. There were transient, mild, nontreatment-limiting rashes attributed to study drugs in 2 patients, 1 during therapy with amprenavir and abacavir and [6] . Efavirenz regimen not evaluable (NE) for patients 7 and 9 because they did not receive efavirenz, and for patient 11 because his viral burden at addition was 590 copies/mL. Del, deletion; ND, not done.
a Began efavirenz 1 week after amprenavir and abacavir. b Had viral load decrease of 1.3 (patient 5) and 0.73 (patient 7) log 10 after adding indinavir back to regimen c Had 2.22 log 10 decrease on a regimen including saquinavir, ritonavir, and nevirapine before efavirenz-based regimen.
1 during therapy with amprenavir, abacavir, and efavirenz. One patient developed bilateral palmar fasciitis and, ultimately, Dupuytren's contracture during the study. Six of 11 patients had minor gastrointestinal symptoms, and 2 had circumoral paresthesia. Among 6 of 9 patients who received efavirenz, the agent was associated with mild CNS effects including headache, dizziness, lightheadedness, confusion, drowsiness, and/or vertigo. Pharmacokinetics. For insight into potential reasons for failure of the indinavir-containing regimen, trough concentrations for indinavir were determined on at least 2 occasions in 9 of the 11 patients before entry into this study. Only 1 trough concentration was 1140 ng/mL, a level that has correlated with efficacy in 2 small studies [13, 14] . The other trough concentrations ranged from undetectable to 115 ng/mL.
The effect of efavirenz on the disposition of amprenavir is shown in table 2. Overall, mean steady-state AUC (AUCss), maximum plasma concentration (Cmax), and minimum plasma concentration (Cmin) decreased by 24%, 33%, and 43%, respectively, in the presence of efavirenz. A further analysis revealed 2 distinct subpopulations in terms of the potential for a drug interaction. Those patients having amprenavir AUCss 120 g/ had the largest decreases in amprenavir exposure mL 7 h during combination therapy. Patients with lower AUCss at baseline (!20 g/ ) demonstrated smaller percentage demL 7 h creases or, in 1 patient, an increased AUC in the presence of efavirenz. Efavirenz concentrations obtained in the presence of amprenavir were comparable with published values for efavirenz monotherapy (data not shown) [15] . Antiviral response. A summary of each patient's response to abacavir and amprenavir and then to an efavirenz-containing regimen is provided in table 1. Ten patients were evaluable for assessment of the response to amprenavir and abacavir therapy, and viral load declined at least 1.5 log 10 in 3 of them. Patient 1 maintained a 0.5-1 log 10 decrease for 28 weeks, at which time efavirenz was added to his regimen. Only patient 9's viral load decreased below the limit of detection of the assay. Efavirenz was added to the abacavir and amprenavir regimen in 9 patients; 2 patients elected to continue their abacavir and amprenavir regimen without adding efavirenz. Another protease inhibitor to which the patient's virus had not previously been exposed was included in addition to efavirenz. Six patients added nelfinavir, 5 at standard doses and 1 at 1250 mg twice daily, and 2 added ritonavir, 1 at 400 mg and 1 at 600 mg twice daily. One patient began efavirenz after a week of amprenavir and abacavir; he later added indinavir. Addition of efavirenz plus a protease inhibitor resulted in a 10.5 log 10 decrease in viral load in 8 of 8 evaluable patients (patient 11 had a viral burden of 590 copies/mL at start, and thus was not evaluable NOTE. Data are IC 50 , mM (fold changes in IC 50 value compared with wt). IC 50 determined by use of phytohemagglutinin-stimulated peripheral blood mononuclear cells exposed to HIV-1 (50 TCID 50 dose, 10 5 PBMC) and by use of inhibition of p24 gag protein production as an end point. Mean of triplicate determinations is presented. IC 50 , drug concentrations that resulted in 50% inhibition; wt, wild type (a clinical HIV-1 strain [HIV-1 ERS104pre ]). for a 0.5 log 10 decline). Six patients had a maximum decline of 11 log 10 copies/mL, and 5 had a decrease below the limit of the assay (500 copies/mL). Response (at least 0.5 log 10 decline in viral load) persisted for у24 weeks in 3 patients; 1 patient remains below the level of detection at 97 weeks, and 1 maintained a 11.5 log 10 decrease from baseline for 90 weeks.
Genotype analysis. Ten patients had genotypic analysis performed on virus in their plasma р6 weeks before abacavir and amprenavir therapy and then again between 8 and 12 weeks after initiation of these agents. In 9 of 10 patients, the virus had important mutations in both the RT and protease genes at baseline (table 1) . For the RT gene, 8 had a mutation at codon 184, a lamivudine resistance site, and 9 had mutations in at least 3 of the following sites of zidovudine resistance: 41, 67, 70, 210, 215, or 219. Few treatment-emergent mutations in RT and none in the protease gene were observed (data not shown).
Phenotype analysis. Phenotyping to zidovudine, abacavir, indinavir, and amprenavir was performed on isolates from 8 patients; these were obtained from 8 to 28 weeks after beginning abacavir and amprenavir (table 3) . If resistance is defined as an IC 50 110-fold times that of wild type virus, then all isolates were highly resistant to all drugs tested, except for patient 5's isolate to abacavir (10-fold), patient 9's isolate to indinavir (10-fold), and patient 10's isolate to zidovudine (4-fold). The isolates from patients 8 and 9, who had the greatest antiviral response of those with phenotype data, were relatively susceptible to both abacavir and amprenavir, compared with isolates from the other patients, even though these samples were obtained at weeks 8 and 9 of therapy.
Discussion
In this pilot study, patients whose indinavir-containing regimen had failed received amprenavir, abacavir, and efavirenz to assess the safety, drug interactions, and antiretroviral activity of this regimen. As predicted based on cytochrome P-450 metabolism, efavirenz decreased plasma amprenavir concentrations (AUCss, Cmax, and Cmin). There was substantial between-patient variability, and patients with the highest amprenavir levels had the largest decrease when efavirenz was added. Such an effect has also been observed with indinavir after adding nevirapine [16] . Abacavir pharmacokinetics were not studied, but since abacavir is not metabolized by the cytochrome P-450 system, interaction is not expected. Efavirenz concentrations during amprenavir therapy were similar to published concentrations obtained during efavirenz monotherapy, suggesting that amprenavir does not substantially alter efavirenz pharmacokinetics [15] . Efavirenz levels were evaluated on days 7-8 of dosing (after 6-7 doses), or after at least 3 times the half-life of efavirenz. Thus, 90% of steady-state plasma concentration should have been reached in all subjects. It is possible but unlikely that sampling at steady state would have resulted in even lower amprenavir concentrations because of achievement of greater enzyme induction.
Cmin and time above IC 95 are generally considered the most important pharmacokinetic parameters for protease inhibitors. The 43% decrease in amprenavir Cmin suggests that the amprenavir dose should be increased to 1200 mg t.i.d. when am-prenavir and efavirenz are given concurrently, but this has not yet been tested. The use of ritonavir or nelfinavir to inhibit amprenavir metabolism and thus to counteract the efavirenzassociated enzyme induction that reduces amprenavir levels is currently being assessed.
The combinations of abacavir and amprenavir and/or abacavir, amprenavir, and efavirenz were well tolerated. No unexpected toxicities were recognized when the 3 drugs were used concurrently. However, in this study, only 1 of 11 heavily pretreated patients had an antiretroviral response that was sustained for at least 24 weeks, despite the administration of a regimen that included abacavir and amprenavir. Therefore, the resistance mutations arising from prior nucleoside RT inhibitor and protease inhibitor therapies resulted in cross-resistance and lack of efficacy. The efavirenz-based regimens were more successful in these relatively NNRTI-naive patients, only 1 of whom had the primary efavirenz mutation K103N in the viral RT at baseline.
Significant mutations in the RT and the protease-encoding genes were found in the virus from 9 of 10 patients. The fact that only 1 patient had optimal trough indinavir levels before study entry suggests that poor absorption or nonadherence were factors in the development of resistance to indinavir in these patients. The patient whose virus had no significant mutations in either region failed to respond (patient 11). His indinavir levels were below the level of detection before study entry, and perhaps nonadherence led to drug failure without evidence of protease-inhibitor resistance. Six other patients had no response to abacavir and amprenavir, and 3 had only a transient response, despite the absence in all viruses tested of a mutation at codon 50 of the protease gene, an important codon for in vitro resistance to amprenavir, and at protease codons 84 or 47, reported to be sites of secondary amprenavir mutations [6, 17] . Resistance to abacavir is associated with mutations at RT codons 65, 74, 115, and 184 [18] , but none of our patients had mutations at codons 65 or 115. The number of baseline RT mutations correlates with phenotypic susceptibility to abacavir [19] , and all but 1 (nonresponder) patient studied harbored virus with multiple mutations in the RT gene.
It is clear that treatment with other nucleoside analogs and other protease inhibitors can produce resistance to abacavir and amprenavir. In addition to the poor viral load response seen in our patients, this is supported by the fact that new mutations in the protease gene did not emerge after treatment failure, despite failure to suppress the viral load, and by the documentation of phenotypic resistance. The greater success of the efavirenz-based regimens might be explained by the fact that virus from only 2 patients had a baseline mutation at sites correlated with resistance to NNRTI agents. Clearly more information is needed to predict a patient's response to a proposed regimen.
A combination regimen that includes abacavir, amprenavir, and efavirenz is well tolerated, but amprenavir doses should be adjusted when concurrent efavirenz is given.
